Skip to main content
Equibles
EHC logo

EHC · Encompass Health Corp · Metrics

Track EHC — free

Use EHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$124.09 -1.92 (-1.52%) At close · Oct 23
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$12.24B
Shares
98.65M
Volume · Oct 23 805.92K Avg daily vol (3M) 949.73K

EHC metrics

107 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$124.09
Market cap
$12.24B

Price action

20 metrics
Price change (1W)
-3.0%
Price change (30D)
+0.5%
Price change (3M)
+9.9%
Price change (6M)
+21.7%
Price change (YTD)
+16.9%
Price change (1Y)
-1.8%
Trailing year
Price change (5Y)
—
52-week high
$127.87
52-week low
$93.83
Change from 52-week high
-3.0%
Change from 52-week low
+32.2%
Annualized volatility
29.8%
Annualized volatility (3M)
32.8%
Beta
0.1
RSI (14D)
52.2
Price vs SMA 50
+1.4%
Price vs SMA 200
+13.4%
Avg volume (3M)
949,731
Relative volume
0.9
Average dollar volume
$115.42M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
98.65M

Valuation

12 metrics
P / E (TTM)
20.2
Trailing earnings · reciprocal yield 4.9%
PEG ratio
1.9
EV / revenue
2.4×
reciprocal yield 42.0%
EV / EBITDA
19.1×
reciprocal yield 5.2%
EV / EBIT
27.8×
reciprocal yield 3.6%
P / sales
2.0×
reciprocal yield 50.7%
P / book
4.7
reciprocal yield 21.2%
FCF yield
3.4%
TTM · current market cap
Buyback yield
2.0%
P / FCF
29.6
reciprocal yield 3.4%
P / operating cash flow
10.1
reciprocal yield 9.9%
Earnings yield
5.1%

Historical valuation

8 metrics
P / E historical average (3Y)
21.3×
reciprocal yield 4.7%
P / E historical average (5Y)
20.9×
reciprocal yield 4.8%
EV / revenue historical average (3Y)
2.3×
reciprocal yield 44.0%
EV / revenue historical average (5Y)
2.1×
reciprocal yield 47.2%
EV / EBIT historical average (3Y)
17.9×
reciprocal yield 5.6%
EV / EBIT historical average (5Y)
17.5×
reciprocal yield 5.7%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
0.6%
Trailing 12 months
Payout ratio
12.1%
Shareholder yield
2.6%
Dividend / share (TTM)
$0.78
Dividend growth YoY
+11.4%
Dividend growth streak
1
Last ex-dividend
2026-10-01

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
10.0%
Gross profit (TTM)
—
Operating profit (TTM)
$539.50M
Net income (TTM)
$621.00M
Trailing 12 months
Diluted EPS (TTM)
$6.14
FCF margin
6.7%
Effective tax rate
20.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$61.32
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$5.37
EBITDA per diluted share (TTM)
$7.80
Net income per diluted share (TTM)
$6.14
Operating cash flow per diluted share (TTM)
$11.97
Free cash flow per diluted share (TTM)
$4.08
Capital expenditures per diluted share (TTM)
$7.89
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.57
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+9.6%
Year over year
Net income growth YoY
+8.3%
Revenue (TTM)
$6.21B
Trailing 12 months
EPS growth YoY
+10.8%
Shares change YoY
-2.2%
Year over year · fewer shares
Revenue CAGR (3Y)
+10.9%
Revenue CAGR (5Y)
+10.7%
EPS CAGR (3Y)
+27.1%
EPS CAGR (5Y)
+14.2%
FCF CAGR (3Y)
+46.0%
FCF CAGR (5Y)
+7.1%

Quality

14 metrics
Return on equity
23.9%
Return on assets
8.3%
Debt / equity
1.0
Current ratio
1.2
EBITDA (TTM)
$783.10M
Free cash flow (TTM)
$413.40M
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
3.5
Return on invested capital
—
Trailing 12 months
Net cash
−$2.53B
Latest balance sheet
Cash & equivalents
$107.70M
Total assets
$7.46B
Total debt
$2.63B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.21B
Capital expenditures (TTM)
$799.10M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$58.00M
R&D / revenue
—
Stock compensation / revenue
0.9%

Ownership (13F)

9 metrics
13F filers
602
13F filer change QoQ
+18
Institutional ownership
97.1%
Conviction holders (share of 13F filers)
0.5%
Crowding (high-turnover and private-fund holders)
31.5%
Private-fund adviser ownership
29.9%
Active holders' share change QoQ
-2.0%
Holder tenure
17.0
Price vs estimated holder cost
-0.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
19.9%

Short interest

3 metrics
Short interest
3.5%
Latest settlement · 3.6 days to cover
Days to cover
3.6d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$26.43M
Insider-sentiment score
8 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 785161 CUSIP 29261A100 13F (30d) 123 filings 118 filers Visit website Investor relations